Skip to main content

Table 1 Dose escalation scheme

From: A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Dose level

Escalation scheme [μg]

No. of pts

1 a

10-50-100-100-100

3–6

2

10-50-100-100-150

3–6

3

10-50-100-150-150

3–6

4

20-50-100-150-150

3–6

5 a

20-50-100-150-200

3–6

6

20-50-100-150-250

3–6

7

20-50-100-200-200

3–6

8

50-100-150-200-200

3–6

9 a

20-50-100-200-300

3–6

10

20-50-100-200-350

3–6

11

50-100-100-150-200

3–6

12

50-100-150-200-200

3–6

13 a

50-100-150-200-300

3–6

14

50-100-150-300-300

3–6

15

50-150-150-300-300

3–6

16

50-150-300-400-500

3–6

  1. Abbreviations: Pts patients
  2. aMain cohort